Gemcitabine With or Without Exatecan Mesylate in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer
Status:
Completed
Trial end date:
2005-04-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so
they stop growing or die. It is not yet known if gemcitabine is more effective with or
without exatecan mesylate in treating pancreatic cancer.
PURPOSE: Randomized phase III trial to compare the effectiveness of gemcitabine alone to that
of gemcitabine and exatecan mesylate in treating patients who have locally advanced or
metastatic pancreatic cancer.